September 30, 2019 07:07 AM EDT
R&D

Charg­ing at block­buster Ad­vair, No­var­tis boasts topline vic­to­ries for asth­ma drugs in twin PhI­II stud­ies

Amber Tong

In a bit of a Rus­sain nest­ing doll mo­ment, No­var­tis says that its po­ten­tial block­buster asth­ma drug has beat an­oth­er treat­ment from its port­fo­lio, which …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

FDA ap­proves sub­cu­ta­neous ver­sion of Bris­tol My­er­s' Op­di­vo

J&J part­ners on STAT6; As­traZeneca, Dai­ichi with­draw lung can­cer drug EMA app

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

A service from the Financial Times